Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial

PURPOSE: The Programmed Death-1 (PD-1) immune checkpoint pathway may be usurped by tumors, including diffuse large B-cell lymphoma (DLBCL), to evade immune surveillance. The reconstituting immune landscape after autologous hematopoietic stem-cell transplantation (AHSCT) may be particularly favorable...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
الحاوية / القاعدة:J Clin Oncol
المؤلفون الرئيسيون: Armand, Philippe, Nagler, Arnon, Weller, Edie A., Devine, Steven M., Avigan, David E., Chen, Yi-Bin, Kaminski, Mark S., Holland, H. Kent, Winter, Jane N., Mason, James R., Fay, Joseph W., Rizzieri, David A., Hosing, Chitra M., Ball, Edward D., Uberti, Joseph P., Lazarus, Hillard M., Mapara, Markus Y., Gregory, Stephanie A., Timmerman, John M., Andorsky, David, Or, Reuven, Waller, Edmund K., Rotem-Yehudar, Rinat, Gordon, Leo I.
التنسيق: Artigo
اللغة:Inglês
منشور في: American Society of Clinical Oncology 2013
الموضوعات:
ORIGINAL REPORTS
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC4878008/
https://ncbi.nlm.nih.gov/pubmed/24127452
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2012.48.3685
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة